Immunotherapy has emerged as a crucial approach in cancer treatment, particularly through targeting immune checkpoints such as programmed cell death protein 1 (PD-1) and its ligand programmed cell death 1 ligand 1 (PD-L1). Here, PDCD1 is linked to cancer.